PA
TXG icon

Parallel Advisors’s 10x Genomics TXG Stock Holding History

Parallel Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.8K Buy
2,604
+43
+2% +$1.13K ﹤0.01% 1713
2026
Q1 		$54.4K Hold
2,561
– – ﹤0.01% 1950
2025
Q4 		$41.8K Buy
2,561
+55
+2% +$831 ﹤0.01% 1927
2025
Q3 		$29.3K Hold
2,506
– – ﹤0.01% 2068
2025
Q2 		$29K Sell
2,506
-15,082
-86% -$137K ﹤0.01% 2014
2025
Q1 		$154K Buy
17,588
+2,686
+18% +$33.9K ﹤0.01% 1071
2024
Q4 		$214K Sell
14,902
-2,321
-13% -$36.6K ﹤0.01% 905
2024
Q3 		$389K Buy
17,223
+1,118
+7% +$23.1K 0.01% 664
2024
Q2 		$313K Sell
16,105
-489
-3% -$12.8K 0.01% 702
2024
Q1 		$623K Sell
16,594
-7
-0% -$308 0.02% 468
2023
Q4 		$929K Sell
16,601
-773
-4% -$33.6K 0.03% 350
2023
Q3 		$717K Buy
17,374
+4
+0% +$208 0.02% 374
2023
Q2 		$970K Sell
17,370
-9
-0.1% -$487 0.03% 318
2023
Q1 		$970K Sell
17,379
-3,010
-15% -$141K 0.03% 316
2022
Q4 		$743K Buy
20,389
+154
+0.8% +$5.04K 0.03% 314
2022
Q3 		$576K Buy
20,235
+69
+0.3% +$2.63K 0.03% 358
2022
Q2 		$913K Sell
20,166
-68
-0.3% -$3.53K 0.04% 259
2022
Q1 		$1.51M Buy
20,234
+12,810
+173% +$1.12M 0.06% 206
2021
Q4 		$1.11M Buy
7,424
+7,414
+74,140% +$1.14M 0.04% 255
2021
Q3 		$1K Sell
10
-1
-9% -$172 ﹤0.01% 2969
2021
Q2 		$2K Sell
11
-3,469
-100% -$628K ﹤0.01% 2624
2021
Q1 		$630K Buy
3,480
+3,462
+19,233% +$598K 0.03% 310
2020
Q4 		$3K Buy
+18
New +$2.61K ﹤0.01% 2227

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Parallel Advisors's TXG Position: Q2 2026 in Review

Parallel Advisors increased its 10x Genomics (TXG) stake by 1.7% in Q2 2026, buying an estimated $1.13K and bringing the position to 2,604 shares worth $99.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1713.

Parallel Advisors first reported a position in TXG in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.51M in Q1 2022. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Parallel Advisors held 2,604 shares of 10x Genomics worth $99.8K as of Q2 2026.
  • Parallel Advisors bought 43 10x Genomics shares in Q2 2026, an estimated $1.13K.
  • 10x Genomics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1713 holding.
  • Parallel Advisors first reported a position in 10x Genomics in Q4 2020 and has held it in 23 quarters since.
  • Parallel Advisors's 10x Genomics position peaked at $1.51M in Q1 2022.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.